Amydis Awarded Third Grant From The Michael J. Fox Foundation To Support First-In-Human Study of a Retinal Tracer for Parkinson’s Disease SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Amydis Inc., a privately held clinical-stage company pioneering a platform of diagnostic drug candidates targeting molecular biomarkers in the eye, today...

Amydis Receives NIH Grant Award to Develop a Novel Tau Retinal Tracer for Alzheimer's Diseases and other Tauopathies SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye,...

Amydis Receives $3 Million NIH Commercialization Readiness Pilot Grant Award for Novel Amyloid Beta Retinal Tracer in Cerebral Amyloid Angiopathy SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye,...